Go Pro

Conduit Pharmaceuticals (CDTTW) 10K Form and Latest SEC Filings 2026

$0.01 +0.00 (+28.28%)
As of 09/23/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Conduit Pharmaceuticals SEC Filings & Recent Activity

Conduit Pharmaceuticals (NASDAQ:CDTTW) has submitted 215+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Conduit Pharmaceuticals's financial statements. The most recent filing was a Form 424B3 submitted on September 18, 2026.

Form 4
CDT Equity Inc. Reports Ownership Change on Sep. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Conduit Pharmaceuticals Files Current Report on Sep. 18, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Conduit Pharmaceuticals Files Quarterly Report on Aug. 12, 2026

The 10-Q contains Conduit Pharmaceuticals's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Conduit Pharmaceuticals SEC Filing History

Browse Conduit Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/18/2026 4:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2026 4:20 PM
Conduit Pharmaceuticals (1896212) Filer
Form 424B3
09/18/2026 3:30 PM
Conduit Pharmaceuticals (1896212) Filer
Form 424B3
09/17/2026 11:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form EFFECT
09/09/2026 5:09 PM
Conduit Pharmaceuticals (1896212) Subject
Wigglesworth Craig Stuart (2154266) Filed by
Form SCHEDULE 13G
09/08/2026 4:30 PM
Conduit Pharmaceuticals (1896212) Filer
Form S-1
Registration statement under Securities Act of 1933  
09/04/2026 3:05 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/02/2026 5:10 PM
Conduit Pharmaceuticals (1896212) Subject
Corvus Capital Ltd. (1990829) Filed by
Form SCHEDULE 13D/A
09/02/2026 5:12 PM
Conduit Pharmaceuticals (1896212) Issuer
Regan Andrew (1991325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 5:16 PM
Conduit Pharmaceuticals (1896212) Subject
Taylor Mark Andrew (2119432) Filed by
Form SCHEDULE 13G
09/01/2026 3:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/01/2026 7:00 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2026 4:26 PM
Conduit Pharmaceuticals (1896212) Subject
Primary Development Fund (0) Cayman
Form SCHEDULE 13G
08/21/2026 4:29 PM
Conduit Pharmaceuticals (1896212) Subject
Primary Development Fund (0) Cayman
Form SCHEDULE 13G
08/21/2026 8:27 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K/A
08/21/2026 8:27 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K/A
08/12/2026 4:29 PM
Conduit Pharmaceuticals (1896212) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2026 3:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form DEFA14A
08/11/2026 7:45 AM
Conduit Pharmaceuticals (1896212) Filer
Form DEF 14A
08/11/2026 7:49 AM
Conduit Pharmaceuticals (1896212) Filer
Form ARS
07/31/2026 4:26 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 4:29 PM
Conduit Pharmaceuticals (1896212) Filer
Form PRE 14A
07/16/2026 7:05 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/15/2026 3:46 PM
Conduit Pharmaceuticals (1896212) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/07/2026 4:20 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/29/2026 3:30 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2026 5:40 PM
Conduit Pharmaceuticals (1896212) Issuer
Prospect Capital Securities Ltd (2120744) Reporting
Prospect Finance Ltd (2120961) Reporting
Taylor Mark Andrew (2119432) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2026 5:42 PM
Conduit Pharmaceuticals (1896212) Subject
Taylor Mark Andrew (2119432) Filed by
Form SCHEDULE 13D/A
06/16/2026 4:00 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2026 7:51 PM
Ascent Partners Fund LLC (2059960) Filed by
Conduit Pharmaceuticals (1896212) Subject
Form SCHEDULE 13G
05/20/2026 6:03 PM
Conduit Pharmaceuticals (1896212) Subject
Nirland Ltd (1994188) Filed by
Form SCHEDULE 13G
05/14/2026 7:42 AM
Conduit Pharmaceuticals (1896212) Issuer
Regan Andrew (1991325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 7:47 AM
Conduit Pharmaceuticals (1896212) Subject
Corvus Capital Ltd. (1990829) Filed by
Form SCHEDULE 13D/A
05/03/2026 11:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form EFFECT
05/01/2026 4:11 PM
Conduit Pharmaceuticals (1896212) Filer
Form 424B3
04/30/2026 7:16 PM
Conduit Pharmaceuticals (1896212) Issuer
Olsen Ulrik K (2132215) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/21/2026 8:56 PM
Conduit Pharmaceuticals (1896212) Filer
Form S-3
Registration statement under Securities Act of 1933  
04/15/2026 4:01 PM
Conduit Pharmaceuticals (1896212) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/30/2026 8:21 PM
Conduit Pharmaceuticals (1896212) Subject
Taylor Mark Andrew (2119432) Filed by
Form SCHEDULE 13D
03/30/2026 8:22 PM
Conduit Pharmaceuticals (1896212) Issuer
Prospect Capital Securities Ltd (2120744) Reporting
Prospect Finance Ltd (2120961) Reporting
Taylor Mark Andrew (2119432) Reporting
Taylor Mark Andrew (2119432) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/30/2026 8:23 PM
Conduit Pharmaceuticals (1896212) Issuer
Prospect Capital Securities Ltd (2120744) Reporting
Prospect Capital Securities Ltd (2120744) Reporting
Prospect Finance Ltd (2120961) Reporting
Taylor Mark Andrew (2119432) Reporting
Taylor Mark Andrew (2119432) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Why I believe the AI market will split in Q4 (Ad)

Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing.tc pixel

Watch the free briefing on the AI market split now
03/25/2026 7:15 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/18/2026 3:53 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2026 3:12 PM
Conduit Pharmaceuticals (1896212) Filer
Form DEF 14A
02/24/2026 3:53 PM
Conduit Pharmaceuticals (1896212) Filer
Form PRE 14A
02/23/2026 7:27 PM
Conduit Pharmaceuticals (1896212) Issuer
Farley Chele Chiavacci (1908750) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 5:26 PM
Ascent Partners Fund LLC (2059960) Filed by
Conduit Pharmaceuticals (1896212) Subject
Form SCHEDULE 13G
02/09/2026 11:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form EFFECT
01/30/2026 8:06 AM
Conduit Pharmaceuticals (1896212) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/22/2026 3:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 3:30 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/22/2025 3:05 PM
Conduit Pharmaceuticals (1896212) Subject
Corvus Capital Ltd. (1990829) Filed by
Form SCHEDULE 13D/A
12/22/2025 3:05 PM
Conduit Pharmaceuticals (1896212) Issuer
Corvus Capital Ltd. (1990829) Reporting
Regan Andrew (1991325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 3:15 PM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 3:46 PM
Conduit Pharmaceuticals (1896212) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/09/2025 7:15 AM
Conduit Pharmaceuticals (1896212) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Conduit Pharmaceuticals SEC Filings - Frequently Asked Questions

Conduit Pharmaceuticals (CDTTW) has submitted 215+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 424B3 submitted on September 18, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:CDTTW are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/18/2026. New filings are added as they're published.
From Our Partners